Insulet Corporation $PODD Stock Position Raised by Assetmark Inc.

Assetmark Inc. grew its holdings in Insulet Corporation (NASDAQ:PODD) by 109.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 529 shares of the medical instruments supplier’s stock after acquiring an additional 276 shares during the period. Assetmark Inc.’s holdings in Insulet were worth $166,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PODD. American Century Companies Inc. increased its position in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after buying an additional 297,734 shares during the period. Nuveen LLC acquired a new stake in shares of Insulet in the first quarter worth $74,163,000. Kayne Anderson Rudnick Investment Management LLC increased its position in Insulet by 1,316.5% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after acquiring an additional 179,850 shares during the period. Vanguard Group Inc. increased its position in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after acquiring an additional 178,976 shares during the period. Finally, AustralianSuper Pty Ltd raised its stake in Insulet by 487.5% during the 2nd quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock valued at $64,460,000 after purchasing an additional 170,247 shares during the last quarter.

Insider Activity

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research note on Friday. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. increased their target price on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. BTIG Research reaffirmed a “buy” rating and issued a $370.00 price target on shares of Insulet in a research note on Thursday. Finally, Rothschild & Co Redburn upped their price target on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.76.

Insulet Stock Down 1.1%

PODD stock opened at $319.82 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The stock has a market capitalization of $22.51 billion, a P/E ratio of 97.21, a P/E/G ratio of 2.64 and a beta of 1.39. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $353.50. The business has a 50-day moving average of $325.06 and a 200-day moving average of $309.86.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet’s quarterly revenue was up 29.9% on a year-over-year basis. During the same quarter last year, the company posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.